TY - JOUR
T1 - Characterisation of non-carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae based on their clinical and molecular profile in Malaysia
AU - Lee, Yee Qing
AU - Sri La Sri Ponnampalavanar, Sasheela
AU - Chong, Chun Wie
AU - Karunakaran, Rina
AU - Vellasamy, Kumutha Malar
AU - Abdul Jabar, Kartini
AU - Kong, Zhi Xian
AU - Lau, Min Yi
AU - Teh, Cindy Shuan Ju
N1 - Funding Information:
This research was funded by the Ministry of Higher Education (Malaysia), Fundamental Research Grant Scheme (FRGS) 2018 (FRGS/1/2018/SKK11/UM/02/4) under project code FP013-2018A and the International Funding (IF066-2020).
Publisher Copyright:
© 2022 by the authors.
PY - 2022/11
Y1 - 2022/11
N2 - Non-carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae (NC-CRKP) confers carbapenem resistance through a combination of chromosomal mutations and acquired non-carbapenemase resistance mechanisms. In this study, we aimed to evaluate the clinical and molecular profiles of NC-CRKP isolated from patients in a tertiary teaching hospital in Malaysia from January 2013 to October 2019. During the study period, 54 NC-CRKP-infected/colonised patients’ isolates were obtained. Clinical parameters were assessed in 52 patients. The all-cause in-hospital mortality rate among NC-CRKP patients was 46.2% (24/52). Twenty-three (44.2%) patients were infected, while others were colonised. Based on the Charlson Comorbidity Index (CCI) score, 92.3% (48/52) of the infected/colonised patients had a score of ≥ 1. Resistance genes found among the 54 NC-CRKP isolates were blaTEM, blaSHV, blaCTX-M, blaOXA, and blaDHA. Porin loss was detected in 25/54 (46.3%) strains. None of the isolated strains conferred carbapenem resistance through the efflux pumps system. In conclusion, only 25/54 (46.3%) NC-CRKP conferred carbapenem resistance through a combination of porin loss and the acquisition of non-carbapenemase resistance mechanisms. The carbapenem resistance mechanisms for the remaining strains (53.7%) should be further investigated as rapid identification and distinction of the NC-CRKP mechanisms enable optimal treatment and infection control efforts.
AB - Non-carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae (NC-CRKP) confers carbapenem resistance through a combination of chromosomal mutations and acquired non-carbapenemase resistance mechanisms. In this study, we aimed to evaluate the clinical and molecular profiles of NC-CRKP isolated from patients in a tertiary teaching hospital in Malaysia from January 2013 to October 2019. During the study period, 54 NC-CRKP-infected/colonised patients’ isolates were obtained. Clinical parameters were assessed in 52 patients. The all-cause in-hospital mortality rate among NC-CRKP patients was 46.2% (24/52). Twenty-three (44.2%) patients were infected, while others were colonised. Based on the Charlson Comorbidity Index (CCI) score, 92.3% (48/52) of the infected/colonised patients had a score of ≥ 1. Resistance genes found among the 54 NC-CRKP isolates were blaTEM, blaSHV, blaCTX-M, blaOXA, and blaDHA. Porin loss was detected in 25/54 (46.3%) strains. None of the isolated strains conferred carbapenem resistance through the efflux pumps system. In conclusion, only 25/54 (46.3%) NC-CRKP conferred carbapenem resistance through a combination of porin loss and the acquisition of non-carbapenemase resistance mechanisms. The carbapenem resistance mechanisms for the remaining strains (53.7%) should be further investigated as rapid identification and distinction of the NC-CRKP mechanisms enable optimal treatment and infection control efforts.
KW - all-cause in-hospital mortality
KW - Charlson Comorbidity Index (CCI)
KW - efflux pump
KW - non-carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae
KW - porin loss
KW - resistance genes
UR - http://www.scopus.com/inward/record.url?scp=85149485938&partnerID=8YFLogxK
U2 - 10.3390/antibiotics11111670
DO - 10.3390/antibiotics11111670
M3 - Article
AN - SCOPUS:85149485938
SN - 2079-6382
VL - 11
JO - Antibiotics
JF - Antibiotics
IS - 11
M1 - 1670
ER -